MetaCap

Celcuity (CELC) vs RadNet (RDNT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

RadNet (RDNT) has outperformed Celcuity (CELC) over the past year, losing 16.0% versus a loss of 45.3%. Over five years, CELC leads with a +249.6% price change compared with +159.6% for RDNT. RadNet is the larger company by market cap ($5.49 billion vs $2.61 billion), about 2.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CELC-45.28%RDNT-16.01%
+53%+2%-50%
Nov 21, 20251 yearNov 20, 2026
CELC+231.99%RDNT+146.33%
+802%+347%-108%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CELC versus RDNT key metrics
MetricCELCRDNT
Share price$53.35$69.71
Market cap$2.61B$5.49B
1-day change-5.26%+0.29%
YTD return-46.51%-2.30%
1-year return-45.28%-16.01%
5-year return+249.61%+159.63%
Forward P/E—66.39
EPS (TTM)$-4.72$-0.29
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$2.04B
Revenue growth (YoY)—+11.51%
Net income (latest FY)$-177.04M$-18.65M
Operating margin—3.04%
Net margin—-0.91%
52-week high$151.02$85.84
52-week low$53.20$50.82
Distance from 52-week high-64.67%-18.79%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+182.76%+39.15%
Average volume1.25M688.04K
Shares outstanding48.93M78.77M
Employees15512,000
SectorHealth CareHealth Care
IndustryMedical SpecialitiesMedical Specialities

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • RadNet is about 2.1 times larger than Celcuity by market value ($5.49B vs $2.61B).
  • RDNT has outperformed CELC by 29.3 percentage points over the past year.

About Celcuity

CELC stock →

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC).

Health Care · Medical Specialities · 155 employees

About RadNet

RDNT stock →

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States and internationally. The company operates in two segments, Imaging Centers and Digital Health.

Health Care · Medical Specialities · 12,000 employees

CELC vs RDNT FAQ

Which is bigger, Celcuity or RadNet?

RadNet (RDNT) is larger, with a market capitalization of $5.49B compared with $2.61B for Celcuity (CELC).

Which stock has performed better over the past year, CELC or RDNT?

RDNT returned -16.01% over the past 12 months, compared with -45.28% for CELC (price return, excluding dividends). Past performance does not predict future results.

Are Celcuity and RadNet in the same industry?

Yes. Both are classified in the Medical Specialities industry within the Health Care sector.

More comparisons